Chronic lymphocytic leukemia

Current Opinion in Hematology

Volumn 7, Issue 4, 2000, Pages 223-234

  Kipps, Thomas J ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ARABINOSIDE; BRYOSTATIN 1; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; DEPSIPEPTIDE; FLUDARABINE; GEMCITABINE; GLUCOCORTICOID; LACTACYSTIN; LOXORIBINE; MAFOSFAMIDE; MELARSOPROL; MITOXANTRONE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 6; RITUXIMAB;

BONE MARROW TOXICITY; CANCER STAGING; CHROMOSOME 11; CHROMOSOME 13; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL RESEARCH; CYTOGENETICS; GENE THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; TRISOMY 12;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD79; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; APOPTOSIS; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN; CLADRIBINE; COMBINED MODALITY THERAPY; CYTOKINES; FEMALE; GENE THERAPY; GENES, IMMUNOGLOBULIN; GENES, P53; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; PROGNOSIS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR STEM CELLS; VIDARABINE;

EID: 0034114985     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200007000-00005     Document Type: Review

References (127)

1. 1 Diehl LF, Karnell LH, Menck HR: The American College of Surgeons Commission on Cancer and the American Cancer Society: the National Cancer Data Base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia. Cancer 1999, 86:2684-2692. This report uses National Cancer Data Base (NCDB) data on patients from a broad spectrum of hospitals in the United States from 1985 to 1990 and from 1991 to 1995. Comparisons were made with US population figures for 1990 and with series published over the last 70 years. Patients with CLL had an average survival age of 69.6 years and comprised 22.6% of the 108,396 cases of leukemia in the database. The risk of developing CLL increased progressively with age and did not plateau. The 5-year relative survival for age groups younger than 40 years of age, 40 to 59, 60 to 79, and older than 80 years of age was 69.5%, 72.2%, 63.1%, and 41.7%, respectively. As such, CLL, not comorbid disease, caused the greatest percentage of deaths. Moreover, CLL is a more fatal disease among older individuals because of the disease itself, not because of comorbid conditions.
2. 2 Adami J, Gridley G, Nyren O, et al.: Sunlight and non-Hodgkin's lymphoma: a population-based cohort study in Sweden. Int J Cancer 1999, 80:641-645.
3. 3 Daibata M, Kamioka M, Wakiguchi H, et al.: Human herpesvirus 7 and lymphocytic leukaemia [letter]. Br J Haematol 1999, 104:934.
4. 4 Paydas S, Kiliç B, Sahin B, et al.: Prevalance of hepatitis C virus infection in patients with lymphoproliferative disorders in Southern Turkey. Br J Cancer 1999, 80:1303-1305.
5. 5 Ansell SM, Li CY, Lloyd RV, et al.: Epstein-Barr virus infection in Richter's transformation. Am J Hematol 1999, 60:99-104.
6. 6 Kobayashi R, Picchio G, Kirven M, et al.: Transfer of human chronic lymphocytic leukemia to mice with severe combined immune deficiency. Leuk Res 1992, 16:1013-1023.
7. 7 Morgan R, Chen Z, Richkind K, et al.: PHA/IL2: an efficient mitogen cocktail for cytogenetic studies of non-Hodgkin lymphoma and chronic lymphocytic leukemia. Cancer Genet Cytogenet 1999, 109:134-137. This study describes an improved mitogen/cytokine cocktail composed of phytohemagglutinin and interleukin 2 that can stimulate proliferation of CLL cells in vitro for use in cytogenetic analysis.
8. 8 Döhner H, Stilgenbauer S, Dohner K, et al.: Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis. J Mol Med 1999, 77:266-281. This is an excellent review of our current understanding of the molecular cytogenetics of CLL.
9. 9 Starostik P, O'Brien S, Chung CY, et al.: The prognostic significance of 13q14 deletions in chronic lymphocytic leukemia. Leuk Res 1999, 23:795-801. This study confirms the prevalence of 13q14 deletion in CLL and suggests that this deletion may identify early stage patients with more aggressive disease.
10. 10 Hogan WJ, Tefferi A, Borell TJ, et al.: Prognostic relevance of monosomy at the 13q14 locus detected by fluorescence in situ hybridization in B-cell chronic lymphocytic leukemia. Cancer Genet Cytogenet 1999, 110:77-81. This study confirms the prevalence of 13q14 deletions in CLL and suggests that patients with this abnormality have a better treatment-free survival than those with trisomy 12.
11. 11 Rondeau G, Moreau I, Bézieau S, et al.: Exclusion of Leu1 and Leu2 genes as tumor suppressor genes in 13q14.3-deleted CLL. Leukemia 1999, 13:1630-1632.
12. 12 Liso V, Capalbo S, Lapietra A, et al.: Evaluation of trisomy 12 by fluorescence in situ hybridization in peripheral blood, bone marrow and lymph nodes of patients with B-cell chronic lymphocytic leukemia. Haematologica 1999, 84:212-217. Using fluorescence in situ hybridization, this study found a higher proportion of trisomy 12 cells in the lymph nodes than in the blood or marrow of CLL patients. As such, it appears that the CLL cells with trisomy 12 may have different cell distributions than CLL cells without this genetic abnormality. This suggests that leukemia cells with trisomy 12 have an enhanced tropism or proliferate advantage in the lymph node.
13. 13 Gahn B, Schafer C, Neef J, et al.: Detection of trisomy 12 and Rb-deletion in CD34+ cells of patients with B-cell chronic lymphocytic leukemia. Blood 1997, 89:4275-4281.
14. 14 Gahn B, Wendenburg B, Troff C, et al.: Analysis of progenitor cell involvement in CLL by simultaneous immunophenotypic and genotypic analysis at the single cell level. Br J Haematol 1999, 105:955-959.
15. 15 Garcia-Marco JA, Price CM, Catovsky D: Interphase cytogenetics in chronic lymphocytic leukemia. Cancer Genet Cytogenet 1997, 94:52-58.
16. 16 Auer RL, Bienz N, Neilson J, et al.: The sequential analysis of trisomy 12 in B-cell chronic lymphocytic leukaemia. Br J Haematol 1999, 104:742-744.
17. 17 Stock AD, Dennis TR: A translocation breakpoint at chromosome band 12q13 associated with B-cell chronic lymphocytic leukemia. Cancer Genet Cytogenet 1999, 111:166-168.
18. 18 Einhorn S, Burvall K, Juliusson G, et al.: Molecular analyses of chromosome 12 in chronic lymphocytic leukemia. Leukemia 1989, 3:871-874.
19. 19 Crossen PE, Horn HL: Origin of trisomy 12 in B-cell chronic lymphocytic leukemia [letter]. Cancer Genet Cytogenet 1987, 28:185-186.
20. 20 Döhner H, Stilgenbauer S, James MR, et al.: 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 1997, 89:2516-2522.
21. 21 Sembries S, Pahl H, Stilgenbauer S, et al.: Reduced expression of adhesion molecules and cell signaling receptors by chronic lymphocytic leukemia cells with 11q deletion. Blood 1999, 93:624-631. This study found that CLL cells with 11q deletion carried significantly lower levels of the adhesion molecules CD11a/CD18 (integrin αL/β2), CD11c/CD18 (integrin αX/β2), CD31 (PECAM-1), CD48, and CD58 (LFA-3) than leukemia cells lacking this genetic abnormality. Furthermore, CLL cells with 11q deletion expressed less the cell signaling receptors CD45 (leukocyte common antigen), CD6, CD35 (complement receptor 1), and CD39. The authors propose that decreased levels of functionally relevant adhesion molecules and of cell signaling receptors may contribute to the pathogenesis of the subgroup of CLL characterized by 11q22-q23 deletion.
22. 22 Thieblemont C, Pack S, Sakai A, et al.: Allelic loss of 11sq13 as detected by MEN1-FISH is not associated with mutation of the MEN1 gene in lymphoid neoplasms. Leukemia 1999, 13:85-91.
23. 23 Zhu Y, Monni O, El-Rifai W, et al.: Discontinuous deletions at 11q23 in B cell chronic lymphocytic leukemia. Leukemia 1999, 13:708-712.
24. 24 Lavin MF, Khanna KK: ATM: the protein encoded by the gene mutated in the radiosensitive syndrome ataxia-telangiectasia. Int J Radiat Biol 1999, 75:1201-1214.
25. 25 Stilgenbauer S, Liebisch P, James MR, et al.: Molecular cytogenetic delineation of a novel critical genomic region in chromosome bands 11q22.3-q23.1 in lymphoproliferative disorders. Proc Natl Acad Sci U S A 1996, 93:11837-11841.
26. 26 Starostik P, Manshouri T, O'Brien S, et al.: Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia. Cancer Res 1998, 58:4552-4557.
27. 27 Bullrich F, Rasio D, Kitada S, et al.: ATM mutations in B-cell chronic lymphocytic leukemia. Cancer Res 1999, 59:24-27. This study found that the ATM gene is mutated in the CLL cells of a fraction of patients. Moreover, these investigators found that such mutations can be present in the germ line DNA of patients, suggesting that ATM heterozygotes may be predisposed to CLL.
28. 28 Bevan S, Yuille MR, Marossy A, et al.: Ataxia telangiectasia gene mutations and chronic lymphocytic leukaemia. Lancet 1999, 353:753.
29. 29 Schaffner C, Stilgenbauer S, Rappold GA, et al.: Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood 1999, 94:748-753. This study examined the germ line DNA of CLL with mutations in the ATM gene at 11q22-q23. In four cases analyzed, the ATM alterations were not present in the germ line. The authors propose that most ATM mutations in CLL are of somatic origin.
30. 30 Stankovic T, Weber P, Stewart G, et al.: Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia [comments]. Lancet 1999, 353:26-29. Germline mutations in the ATM gene at 11q22-q23 were detected in two of six studied CLL patients who had leukemia cells with ATM mutations. The authors suggest that carriers of ATM mutations may be at a particular risk for the development of CLL and that this may partly explain the known genetic susceptibility to this disease.
31. 31 Crossen PE: Genes and chromosomes in chronic B-cell leukemia. Cancer Genet Cytogenet 1997, 94:44-51.
32. 32 Amiel A, Mulchanov I, Elis A, et al.: Deletion of 6q27 in chronic lymphocytic leukemia and multiple myeloma detected by fluorescence in situ hybridization. Cancer Genet Cytogenet 1999, 112:53-56. Using fluorescence in situ hybridization, this study found deletions at 6q27, rather than at 6q23, in leukemia cells of 21% of patients with CLL, suggesting that this genetic abnormality is not specific to intermediate grade lymphomas.
33. 33 Callet-Bauchu E, Salles G, Gazzo S, et al.: Translocations involving the short arm of chromosome 17 in chronic B-lymphoid disorders: frequent occurrence of dicentric rearrangements and possible association with adverse outcome. Leukemia 1999, 13:460-468. By conventional karyotype, this study identified unbalanced translocations involving 17p in 14 out of 123 (11%) CLL/small lymphocytic lymphoma patients with clonal abnormalities. In all cases, translocations led to a monosomy 17p and to a TP53 monoallelic deletion associated with a more adverse clinical outcome.
34. 34 Cordone I, Masi S, Mauro FR, et al.: p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood 1998, 91:4342-4349.
35. 35 Pettitt AR, Sherrington PD, Cawley JC: The effect of p53 dysfunction on purine analogue cytotoxicity in chronic lymphocytic leukaemia. Br J Haematol 1999, 106:1049-1051.
36. H genes (P = .0008). These authors propose that CLL comprises two different diseases with different clinical courses: one, arising from a memory B cell, has a relatively benign course; whereas the other, arising from a naive B cell, is relatively malignant.
37. 37 Damle RN, Wasil T, Fais F, et al.: Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999, 94:1840-1847. This study found that the immunoglobulin variable region gene (V gene) mutation status and the expression levels of CD38 on CLL cells were associated with differences in clinical outcome.
38. 38 Kipps TJ, Tomhave E, Chen PP, et al.: Autoantibody-associated kappa light chain variable region gene expressed in chronic lymphocytic leukemia with little or no somatic mutation: implications for etiology and immunotherapy. J Exp Med 1988, 167:840-852.
39. 39 Schettino EW, Cerutti A, Chiorazzi N, et al.: Lack of intraclonal diversification in Ig heavy and light chain V region genes expressed by CD5+IgM+ chronic lymphocytic leukemia B cells: a multiple time point analysis. J Immunol 1998, 160:820-830.
40. 40 Oscier DG, Thompsett A, Zhu D, et al.: Differential rates of somatic hypermutation in V(H) genes among subsets of chronic lymphocytic leukemia defined by chromosomal abnormalities. Blood 1997, 89:4153-4160.
41. 41 Rassenti LZ, Kipps TJ: Lack of allelic exclusion in B cell chronic lymphocytic leukemia. J Exp Med 1997, 185:1435-1445.
42. 42 Rassenti LZ, Kipps TJ: Expression of Ig-β (CD79b) by chronic lymphocytic leukemia B cells that lack Ig heavy chain allelic exclusion. Blood 2000, 95:2725-2727.
43. 43 Thompson AA, Do HN, Saxon A, et al.: Widespread B29 (CD79b) gene defects and loss of expression in chronic lymphocytic leukemia. Leuk Lymphoma 1999, 32:561-569.
44. 44 Alfarano A, Indraccolo S, Circosta P, et al.: An alternatively spliced form of CD79b gene may account for altered B-cell receptor expression in B-chronic lymphocytic leukemia. Blood 1999, 93:2327-2335. This study found that the low level expression of surface immunoglobulin and associated accessory proteins, CD79a and CD79b, in CLL was associated with expression of a relatively high amount of the alternatively spliced transcript encoding CD79b. Because normal B cells also present this variant, the authors propose that the mechanism of CD79b posttranscriptional regulation might reflect the activation stage of the normal B cell from which CLL derives.
45. 45 Huang JC, Finn WG, Goolsby CL, et al.: CD5-small B-cell leukemias are rarely classifiable as chronic lymphocytic leukemia. Am J Clin Pathol 1999, 111:123-130.
46. 46 Bell PB, Rooney N, Bosanquet AG: CD79a detected by ZL7.4 separates chronic lymphocytic leukemia from mantle cell lymphoma in the leukemic phase. Cytometry 1999, 38:102-105.
47. 47 Gala JL, Guiot Y, Delannoy A, et al.: Use of image analysis and immunostaining of bone marrow trephine biopsy specimens to quantify residual disease in patients with B-cell chronic lymphocytic leukemia. Mod Pathol 1999, 12:391-399.
48. 48 Chen JR, Gu BJ, Dao LP, et al.: Transendothelial migration of lymphocytes in chronic lymphocytic leukaemia is impaired and involved down-regulation of both L-selectin and CD23. Br J Haematol 1999, 105:181-189.
49. 49 Burger JA, Burger M, Kipps TJ: Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 1999, 94:3658-3667. This study found that the chemokine receptor CXCR4 for stromal cell-derived factor-1 (SDF-1) plays a critical role for heterotypic adherence of leukemia cells to marrow stromal cells and provides a new mechanism to account for the marrow infiltration by neoplastic B cells that invariably is seen in patients with CLL.
50. 50 Lampert IA, Wotherspoon A, Van Noorden S, et al.: High expression of CD23 in the proliferation centers of chronic lymphocytic leukemia in lymph nodes and spleen. Human Pathol 1999, 30:648-654.
51. 51 Zimmerman TS, Godwin HA, Perry S: Studies of leukocyte kinetics in chronic lymphocytic leukemia. Blood 1968, 31:277-291.
52. 52 Andreeff M, Darzynkiewicz Z, Sharpless TK, et al.: Discrimination of human leukemia subtypes by flow cytometric analysis of cellular DNA and RNA. Blood 1980, 55:282-293.
53. 53 Kobayashi R, Picchio G, Kirven M, et al.: Transfer of human chronic lymphocytic leukemia to mice with severe combined immune deficiency. Leuk Res 1992, 16:1013-1023.
54. 54 Marschitz I, Tinhofer I, Hittmair A, et al.: Analysis of Bcl-2 protein expression in chronic lymphocytic leukemia: a comparison of three semiquantitation techniques. Am J Clin Pathol 2000, 113:219-229.
55. 55 Pepper C, Thomas A, Hoy T, et al.: Antisense-mediated suppression of Bcl-2 highlights its pivotal role in failed apoptosis in B-cell chronic lymphocytic leukaemia. Br J Haematol 1999, 107:611-615. This study found that a BCL-2 antisense oligonucleotide induced a specific reduction in leukemia-cell expression of bcl-2 and resistance to induced cell death. The authors propose that Bcl-2 antisense oligonucleotides might be useful in the treatment of CLL.
56. 56 Klein A, Miera O, Bauer O, et al.: Chemosensitivity of B cell chronic lymphocytic leukemia and correlated expression of proteins regulating apoptosis, cell cycle and DNA repair. Leukemia 2000, 14:40-46.
57. 57 Stoetzer OJ, Pogrebniak A, Scholz M, et al.: Drug-induced apoptosis in chronic lymphocytic leukemia. Leukemia 1999, 13:1873-1880.
58. 58 Gottardi D, Alfarano A, De Leo AM, et al.: In leukaemic CD5+ B cells the expression of BCL-2 gene family is shifted toward protection from apoptosis. Br J Haematol 1996, 94:612-618.
59. 59 Pepper C, Thomas A, Hoy T, et al.: Chlorambucil resistance in B-cell chronic lymphocytic leukaemia is mediated through failed Bax induction and selection of high Bcl-2-expressing subclones. Br J Haematol 1999, 104:581-588.
60. 60 de la Fuente MT, Casanova B, Garcia-Gila M, et al.: Fibronectin interaction with alpha4beta1 integrin prevents apoptosis in B cell chronic lymphocytic leukemia: correlation with Bcl-2 and Bax. Leukemia 1999, 13:266-274.
61. 61 Schlesinger M, Broman I, Lugassy G: The complement system is defective in chronic lymphatic leukemia patients and in their healthy relatives. Leukemia 1996, 10:1509-1513.
62. 62 Veenstra H, Jacobs P, Dowdle EB: Abnormal association between invariant chain and HLA class II alpha and beta chains in chronic lymphocytic leukemia. Cell Immunol 1996, 171:68-73.
63. 63 Itala M, Vainio O, Remes K: Functional abnormalities in granulocytes predict susceptibility to bacterial infections in chronic lymphocytic leukaemia. Eur J Haematol 1996, 57:46-53.
64. 64 Rezvany MR, Jeddi-Tehrani M, Osterborg A, et al.: Oligoclonal TCRBV gene usage in B-cell chronic lymphocytic leukemia: major perturbations are preferentially seen within the CD4 T-cell subset. Blood 1999, 94:1063-1069.
65. 65 Aittoniemi J, Miettinen A, Laine S, et al.: Opsonising immunoglobulins and mannan-binding lectin in chronic lymphocytic leukemia. Leuk Lymphoma 1999, 34:381-385.
66. 66 Aslakson CJ, Lee G, Boomer JS, et al.: Expression of regeneration and tolerance factor on B cell chronic lymphocytic leukemias: a possible mechanism for escaping immune surveillance. Am J Hematol 1999, 61:46-52.
67. 67 Cantwell MJ, Hua T, Pappas J, et al.: Acquired CD40-ligand deficiency in chronic lymphocytic leukemia. Nature Med 1997, 3:984-989.
68. 68 Kneitz C, Goller M, Wilhelm M, et al.: Inhibition of T cell/B cell interaction by CLL cells. Leukemia 1999, 13:98-104.
69. 69 Lacombe C, Gombert J, Dreyfus B, et al.: Heterogeneity of serum IgG subclass deficiencies in B chronic lymphocytic leukemia. Clin Immunol 1999, 90:128-132.
70. 70 Bernard M, Drenou B, Pangault C, et al.: Spontaneous phenotypic and molecular blood remission in a case of chronic lymphocytic leukaemia. Br J Haematol 1999, 107:213-214.
71. 71 Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials: CLL Trialists' Collaborative Group. J Natl Cancer Inst 1999, 91:861-868. This study compared the effects on survival of the following: 1) immediate versus deferred chemotherapy for early stage CLL; and 2) combination chemotherapy (eg, cyclophosphamide and vincristine plus prednisone/prednisolone [COP] or COP plus doxorubicin [CHOP]), versus single agent chlorambucil as first line treatment for more advanced disease. The results support a conservative treatment strategy for CLL, ie, no chemotherapy for most patients with early stage disease, and single agent chlorambucil as the first line of treatment for most patients with advanced disease, with no evidence of benefit from early inclusion of an anthracycline.
72. 72 Criel A, Michaux L, De Wolf-Peeters C: The concept of typical and atypical chronic lymphocytic leukaemia. Leuk Lymphoma 1999, 33:33-45.
73. 73 Hallek M, Langenmayer I, Nerl C, et al.: Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood 1999, 93:1732-1737.
74. 74 Molica S, Levato D, Cascavilla N, et al.: Clinico-prognostic implications of simultaneous increased serum levels of soluble CD23 and β2-microglobulin in B-cell chronic lymphocytic leukemia. Eur J Haematol 1999, 62:117-122.
75. 75 Everaus H, Luik E, Lehtmaa J: Active and indolent chronic lymphocytic leukaemia-immune and hormonal peculiarities. Cancer Immunol Immunother 1997, 45:109-114.
76. 76 Vlasveld LT, Pauwels P, Ermens AA, et al.: Parathyroid hormone-related protein (PTH-rP)-associated hypercalcemia in a patient with an atypical chronic lymphocytic leukemia. Neth J Med 1999, 54:21-26.
77. 77 Beaudreuil J, Lortholary O, Martin A, et al.: Hypercalcemia may indicate Richter's syndrome: report of four cases and review. Cancer 1997, 79:1211-1215.
78. 78 Mauro FR, Foa R, Giannarelli D, et al.: Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. Blood 1999, 94:448-454.
79. 79 Molica S, Levato D, Dattilo A: Natural history of early chronic lymphocytic leukemia: a single institution study with emphasis on the impact of disease progression on overall survival. Haematologica 1999, 84:1094-1099.
80. 80 Keating MJ: Chronic lymphocytic leukemia. Semin Oncol 1999, 26:107-114.
81. 81 Elliott MA, Letendre L, Li CY, et al.: Chronic lymphocytic leukaemia with symptomatic diffuse central nervous system infiltration responding to therapy with systemic fludarabine. Br J Haematol 1999, 104:689-694.
82. 82 Foran JM, Oscier D, Orchard J, et al: Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia. J Clin Oncol 1999, 17:1574-1579.
83. 83 Mason JM, Drummond MF, Bosanquet AG, et al.: The DiSC assay: a cost-effective guide to treatment for chronic lymphocytic leukemia? Int J Technol Assess Health Care 1999, 15:173-184.
84. 84 Bosanquet AG, Johnson SA, Richards SM: Prognosis for fludarabine therapy of chronic lymphocytic leukaemia based on ex vivo drug response s by DiSC assay. Br J Haematol 1999, 106:71-77.
85. 85 Sen K, Kalaycio M: Evan's syndrome precipitated by fludarabine therapy in a case of CLL [letter]. Am J Hematol 1999, 61:219.
86. 86 Blanche P, Bouscary D, Gombert B, et al.: Successful treatment of acquired factor VIII inhibitor with fludarabine and cyclophosphamide in chronic lymphoid leukemia [letter]. Leukemia 1999, 13:1294.
87. 87 Cheson BD, Vena DA, Barrett J, et al.: Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol 1999, 17:2454-2460.
88. 88 O'Brien S, Kantarjian H, Beran M, et al.: Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia. Leukemia 1997, 11:1631-1635.
89. 89 Giles FJ, O'Brien SM, Santini V, et al.: Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study. Leuk Lymphoma 1999, 36:57-65.
90. 90 Frewin R, Turner D, Tighe M, et al.: Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders. Br J Haematol 1999, 104:612-613.
91. 91 Bellosillo B, Villamor N, Colomer D, et al.: In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood 1999, 94:2836-2843.
92. 92 Pellacani A, Tosi P, Zinzani PL, et al.: Cytotoxic combination of loxoribine with fludarabine and mafosfamide on freshly isolated B-chronic lymphocytic leukemia cells. Leuk Lymphoma 1999, 33:147-153.
93. 93 Tosi P, Pellacani A, Zinzani PL, et al.: In vitro study of the combination gemcitabine + fludarabine on freshly isolated chronic lymphocytic leukemia cells. Haematologica 1999, 84:794-798.
94. 94 Robak T, Blasinska-Morawiec M, Blonski JZ, et al.: 2-Chlorodeoxyadenosine (cladribine) in the treatment of elderly patients with B-cell chronic lymphocytic leukemia. Leuk Lymphoma 1999, 34:151-157.
95. 95 Robak T, Blonski JZ, Urbanska-Rys H, et al.: 2-Chlorodeoxyadenosine (Cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger. Leukemia 1999, 13:518-523.
96. 96 Bosanquet AG, Copplestone JA, Johnson SA, et al.: Response to cladribine in previously treated patients with chronic lymphocytic leukaemia identified by ex vivo assessment of drug sensitivity by DiSC assay. Br J Haematol 1999, 106:474-476.
97. 97 Robak T, Gora-Tybor J, Urbanska-Rys H, et al.: Combination regimen of 2-chlorodeoxyadenosine (cladribine), mitoxantrone and dexamethasone (CMD) in the treatment of refractory and recurrent low grade non-Hodgkin's lymphoma. Leuk Lymphoma 1999, 32:359-363.
98. 98 Van Den Neste E, Bontemps F, Delacauw A, et al.: Potentiation of antitumor effects of cyclophosphamide derivatives in B-chronic lymphocytic leukemia cells by 2-chloro-2′-deoxyadenosine. Leukemia 1999, 13:918-925.
99. 99 Thornton PD, Hamblin M, Treleaven JG, et al.: High dose methyl prednisolone in refractory chronic lymphocytic leukaemia. Leuk Lymphoma 1999, 34:167-170.
100. 100 Konig A, Wrazel L, Warrell RPJ, et al.: Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. Blood 1997, 90:562-570.
101. 101 Soignet SL, Tong WP, Hirschfeld S, et al.: Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemia. Cancer Chemother Pharmacol 1999, 44:417-421.
102. 102 Byrd JC, Shinn C, Ravi R, et al.: Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood 1999, 94:1401-1408. This study indicates that CLL cells may be sensitive to depsipeptide (FR901228) in vitro at drug levels that do not affect normal blood mononuclear cells or stem cells. The authors advocate the early introduction of depsipeptide into clinical trials for patients with CLL.
103. 103 Liu KZ, Schultz CP, Johnston JB, et al.: Infrared spectroscopic study of bryostatin 1-induced membrane alterations in a CLL cell line. Leukemia 1999, 13:1273-1280.
104. 104 Kitada S, Zapata JM, Andreeff M, et al.: Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol 1999, 106:995-1004.
105. 105 Mohammad RM, Limvarapuss C, Hamdy N, et al.: Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine. Int J Oncol 1999, 14:945-950.
106. 106 Masdehors P, Omura S, Merle-Béral H, et al.: Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin. Br J Haematol 1999, 105:752-757. This study found that lactacystin, an inhibitor of ubiquitin-proteasome-dependent protein processing, was toxic for radio-resistant or sensitive CLL cells in vitro, at drug levels that had no effect on normal cells. The authors propose that this agent may be of use in the treatment of CLL.
107. 107 Maloney DG, Grillo-López AJ, White CA, et al.: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997, 90:2188-2195.
108. 108 McLaughlin P, Grillo-López AJ, Link BK, et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825-2833.
109. 109 Yang HH, Rosove MH, Figlin RA: Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Am J Hematol 1999, 62:247-250.
110. 110 Winkler U, Jensen M, Manzke O, et al.: Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8). Blood 1999, 94:2217-2224.
111. 111 Lim LC, Koh LP, Tan P: Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia [letter]. J Clin Oncol 1999, 17:1962-1963.
112. 112 Osterborg A, Dyer MJ, Bunjes D, et al.: Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia: European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997, 15:1567-1574.
113. 113 Otton SH, Turner DL, Frewin R, et al.: Autoimmune thrombocytopenia after treatment with Campath 1H in a patient with chronic lymphocytic leukaemia. Br J Haematol 1999, 106:261-262.
114. 114 Shen S, DeNardo GL, O'Donnell RT, et al.: Impact of splenomegaly on therapeutic response and I-131-LYM-1 dosimetry in patients with B-lymphocytic malignancies. Cancer 1997, 80:2553-2557.
115. 115 DeNardo GL, Lamborn KR, Goldstein DS, et al.: Increased survival associated with radiolabeled Lym-1 therapy for non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Cancer 1997, 80:2706-2711.
116. 116 DeNardo GL, DeNardo SJ, Shen S, et al.: Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J Nucl Med 1999, 40:1317-1326.
117. 117 Brown PD, Diamant M, Jensen PO, et al.: S-phase induction by interleukin-6 followed by chemotherapy in patients with chronic lymphocytic leukemia and non-Hodgkin's lymphoma. Leuk Lymphoma 1999, 34:325-333.
118. 118 de Nully Brown P, Hansen MM: GM-CSF treatment in patients with B-chronic lymphocytic leukemia. Leuk Lymphoma 1999, 32:365-368.
119. 119 Waselenko JK, Flynn JM, Byrd JC: Stem-cell transplantation in chronic lymphocytic leukemia: the time for designing randomized studies has arrived. Semin Oncol 1999, 26:48-61.
120. 120 Schultze JL, Donovan JW, Gribben JG: Minimal residual disease detection after myeloablative chemotherapy in chronic lymphatic leukemia. J Mol Med 1999, 77:259-265.
121. 121 Magnac C, Sutton L, Cazin B, et al.: Detection of minimal residual disease in B chronic lymphocytic leukemia (CLL). Hematol Cell Ther 1999, 41:13-18.
122. 122 Schey S, Ahsan G, Jones R: Dose intensification and molecular responses in patients with chronic lymphocytic leukaemia: a phase II single centre study. Bone Marrow Transplant 1999, 24:989-993.
123. 123 Kato K, Cantwell MJ, Sharma S, et al.: Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest 1998, 101:1133-1141. This study examined the in vitro effects of gene transfer of a recombinant CD40-ligand (CD154) into CLL B cells using an adenovirus vector (Ad-CD154). Transduction of CLL cells with Ad-CD154 induced expression of immune accessory molecules on infected cells and allowed these cells to activate bystander leuekemia B cells into also becoming highly effective antigen-presenting cells. The Ad-CD154-transduced CLL cells could induce autologous T cells to develop cytotoxic activity for noninfected and infected autologous CLL cells in vitro.
124. 124 Ranheim EA, Kipps TJ: Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med 1993, 177:925-935.
125. 125 Buhmann R, Nolte A, Westhaus D, et al.: CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T Cells generates different types of effector cells. Blood 1999, 93:1992-2002. This study stimulated CLL cells by coculture with CD40-ligand bearing "feeder" cells. Treated CLL cells stimulated T-cell proliferation and generation of leukemia-specific cytotoxic T cells in vitro.
126. 126 Kipps TJ: Future strategies toward the cure of indolent B-cell malignancies. Molecular genetic approaches. Semin Hematol 1999, 36:3-8. This report discusses potential strategies for gene therapy of CLL and indolent B-cell malignancies.
127. 127 Wierda WG, Rassenti LZ, Cantwell MD, et al.: A phase I study of CD154 (CD40-ligand) gene therapy for chronic lymphocytic leukemia [abstract]. Blood 1999, 94:602. This report outlines the results of the first trial of gene therapy for patients with CLL, in which autologous Ad-CD154-transduced CLL cells were given as a single intravenous bolus infusion.